The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Iwaku, Akira ^a   Kinoshita, Akiyoshi ^a   Onoda, Hiroshi ^a   Fushiya, Nao ^a   Nishino, Hirokazu ^a   Matsushima, Masato ^b   Tajiri, Hisao ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biliary tract cancer; Glasgow Prognostic Score; Neutrophil to lymphocyte ratio; Prognosis

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SCORING SYSTEM; VERY ELDERLY; AREA UNDER THE CURVE; BILIARY TRACT NEOPLASMS; CELL COUNT; CYTOLOGY; LYMPHOCYTE COUNT; MORTALITY; MULTIVARIATE ANALYSIS; PALLIATIVE THERAPY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BILIARY TRACT NEOPLASMS; CELL COUNT; FEMALE; HUMANS; INFLAMMATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84888784849     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0787-1     Document Type: Article

References (35)

1. Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2012;11:349-59.
2. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006;45:856-67. (Pubitemid 44646688)
3. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11:13.e1-21.e1 quiz e3-4.
4. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-22.
5. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350:1142-3. (Pubitemid 27454010)
6. National Canser Cencer. Cancer statistics in Japan 2009. http://www.fpcr.or.jp/publication/statistics.html Accessed 24 June 2013.
7. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5:191-218. (Pubitemid 32118646)
8. Marino D, Leone F, Cavalloni G, Cagnazzo C, Aglietta M. Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol Hematol. 2013;85:136-48.
9. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32:1757-62.
10. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012;203:101-6.
11. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52-2407-13-52.
12. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97:513-8. (Pubitemid 351631430)
13. Oshiro Y, Sasaki R, Fukunaga K, Kondo T, Oda T, Takahashi H, et al. Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2013;20:389-95.
14. Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6:533-41.
15. Wada K, Takada T, Kawarada Y, Nimura Y, Miura F, Yoshida M, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:52-8. (Pubitemid 46189142)
16. de Marsh RW, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, et al. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol. 2012;106:332-8.
17. Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer. 2009;115:4148-55.
18. Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology. 2010;79:39-45.
19. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64-9. (Pubitemid 34666222)
20. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67:257-62.
21. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Takeda Y, et al. Treatment of borderline cases for curative resection of biliary tract cancer. J Surg Oncol. 2011;104:499-503.
22. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6:149-63.
23. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61:824-33. (Pubitemid 47311721)
24. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208.
25. Maeda S, Hikiba Y, Sakamoto K, Nakagawa H, Hirata Y, Hayakawa Y, et al. Ikappa B kinasebeta/nuclear factor-kappa B activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology. 2009;50:1851-60.
26. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013;57:2224-34.
27. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008;144:729-35.
28. Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913-24.
29. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer. 2011;47:2633-41.
30. Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, et al. Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol. 2013; in press.
31. van der Gaag NA, Kloek JJ, de Bakker JK, Musters B, Geskus RB, Busch OR, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642-9.
32. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651-8.
33. Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215:343-55.
34. Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, et al. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol. 2009;65:113-20.
35. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047-51. (Pubitemid 350179198)